Näky review

What it is

Näky is a LegitScript-approved telehealth platform selling compounded semaglutide and tirzepatide, an uncommon oral semaglutide drops product, a separate GLP-1 microdose program, and a longevity line of sermorelin and NAD⁺ weekly injections. Onboarding is a three-minute assessment with a same-day treatment plan from a licensed provider, free shipping and a dedicated care team, and its collection pages state the policy plainly: same price at every dose, no hidden fees, no surprise charges.

How it works

Asynchronous and quiz-led throughout: a short assessment, same-day provider review, and monthly medication shipped from what the site describes only as USA-based FDA-regulated pharmacies. The longevity products are sold as weekly injections with a choice between annual billing (delivered monthly or quarterly) and month-to-month, and both figures appear together on the collection page — which is the right way to present a prepay discount, because the headline is not the only number shown. What has not improved is company disclosure. Näky publishes no legal entity or state of incorporation, names no compounding pharmacy, and enumerates no states, so eligibility is a question resolved inside the assessment rather than before it. There is one internal inconsistency worth knowing about: the trust bar advertises free two-day shipping while the site's own delivery FAQ describes two to four business days of pharmacy processing followed by three to five days in transit. Those are different promises, and the second one is the operational reality.

Pricing transparency

Sermorelin and NAD⁺ are each 'starting at $185/mo' paid annually with monthly or quarterly delivery, or $195/mo on the month-to-month plan, with the collection page stating the same price at every dose and no hidden or surprise charges. Read the two tiers as they are presented: $185 is the annual-prepay rate, and $195 is what you actually pay if you keep the option to stop. The dose-flat commitment is the substantive claim here, and it is the one to confirm at intake, because it is the difference between a stable bill and one that rises every time a provider steps you up. Näky's GLP-1 pricing is still not published — its treatment and pricing URLs return 404s, and the product cards show 'Get Started' with no figure — so nothing on the weight-loss side can be compared, and none of it is a peptide or NAD⁺ price.

Branded vs compounded

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Näky's pharmacy claim is generic — USA-based, FDA-regulated — rather than a named partner, and compounded preparations are not reviewed by the FDA for purity and potency the way approved drugs are. Its LegitScript approval does verify for the domain, which is a real check on the pharmacy and advertising side without telling you who owns the business. On evidence, the two longevity products sit at different tiers. Sermorelin is a GHRH analogue that stimulates your own pituitary to release growth hormone rather than supplying it, preserving the natural feedback loop — a real, well-described mechanism whose long-term human outcome data remains thin. Injected NAD⁺ is weaker: there are no controlled human outcome trials for injected, intranasal or sublingual NAD⁺, and the forms with human data are the oral precursors NR and NMN, which reliably raise blood NAD⁺, a raised biomarker rather than a demonstrated clinical benefit. Separately, its oral semaglutide drops are a compounded product rather than Rybelsus or any FDA-approved oral semaglutide, so dose equivalence there is an open question worth raising at intake. Individual results vary.

Pros and watch-outs

The evidence behind what Näky prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How Näky compares

A few alternatives worth a look, depending on what you’re optimizing for.

• NUNucific

  Readers weighing NAD⁺ routes who value careful chart disclosure over an upfront price

  See Nucific →
• OHObu Health

  NAD⁺ injections from a platform that names the pharmacies preparing them

  See Obu Health →
• NMNova MD

  NAD⁺ buyers who want the concentration and vial size stated, not just a monthly fee

  See Nova MD →